Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL	primary central nervous system lymphoma	Recruiting	Phase 2 / Phase 3	2026-08-19		NCT07185373

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Changhai Hospital	141
First Affiliated Hospital of Fujian Medical University	88
Henan Cancer Hospital	147
Huashan Hospital	165
Huaxi Hospital	5
Peking University Third Hospital	243
Qilu Hospital of Shandong University	249
RenJi Hospital	264
Shanghai Tongji Hospital, Tongji University School of Medicine	23
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	285
Tang-Du Hospital	93
The First Affiliated Hospital of Nanchang University	84
The Tumor Hospital of Jiangsu Province	2
WuhanUnionHospital	1
Xuanwu Hospital, Beijing	232

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Changhai Hospital	Shanghai	China	21
Department of Hematology, Qilu Hospital of Shandong University	Jinan	China	1
First affiliated hospital of fujian medical university	Fuzhou	China	6
Henan Cancer Hospital	Zhengzhou	China	60
Huashan hospital	Shanghai	China	8
Huaxi Hospital	Chengdu	China	1
Peking University Third Hospital	Beijing	China	71
Renji Hospital	Shanghai	China	12
Shanghai Tongji Hospital, Tongji University School of Medicine	Shanghai	China	2
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Guangzhou	China	2
Tang-Du Hospital	Xi'an	China	1
The First Affiliated Hospital of Nanchang University	Nanchang	China	55
The Tumor Hospital of Jiangsu Province	Nanjing	China	1
WuhanUnionHospital	Wuhan	China	1
Xuanwu Hospital	Beijing	China	8